insights_auto
Nega NTLA tushdi 5,34%?
Batafsil oʻrganishchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
11,71 US$
arrow_downward
-5,34%(-0,66) 1K
11,92 US$
arrow_upward
+1,79% (+0,21)todayBirjadan oldin
Savdolar yopilgan: 7-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNTLA tikeri uchun statistika yaratilmoqda...
Ochish
12,08 US$
Yuqori
12,41 US$
Past
11,70 US$
Bozor kapitali
1,64 mlrd
Oʻrtacha hajm
4,24 mln
Hajmi
9,54 ming
52 haftalik eng yuqori
28,24 US$
52 haftalik eng past
7,95 US$
Aksiya boʻyicha daromad
-3,36 US$
Beta
1,80
Muomaladagi aksiyalar
140,13 mln
Xodimlar soni
377
Ochish
12,08 US$
Yuqori
12,41 US$
Past
11,70 US$
Bozor kapitali
1,64 mlrd
Oʻrtacha hajm
4,24 mln
Hajmi
9,54 ming
52 haftalik eng yuqori
28,24 US$
52 haftalik eng past
7,95 US$
Aksiya boʻyicha daromad
-3,36 US$
Beta
1,80
Muomaladagi aksiyalar
140,13 mln
Xodimlar soni
377
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Benzinga
·
1 kun oldin
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
GuruFocus
·
1 kun oldin
NTLA Initiates Coverage On Barclays -- Rating Set to Underweight
Seeking Alpha
·
2 kun oldin
Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMD (ARKK:BATS)
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc haqida
CEOJohn Leonard
Xodimlar soni377
Asos solingan2014
Bosh ofislarKembrij, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytintelliatx.com